antisecretory

Vonoprazan Fumarate (TAK438) , a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumarate (TAK438) inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.

Lafutidine (FRG-8813) is a newly developed histamine H2-receptor antagonist that inhibits gastric acid secretion.

Vonoprazan (TAK-438 (free base)) is an orally active potassium-competitive acid blocker.Vonoprazan can be used for the treatment of gastroduodenal ulcer and reflux esophagitis

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.

Itriglumide (CR-2945) is a cholecystokinin (CCK)-2 receptor antagonist with antisecretory and antiulcerogenic properties.

Dalcotidine (KU 1257) is a novel histamine H2 receptor antagonist with histamine H9 receptor antagonistic activity and antisecretory effects.The Ki value for binding to guinea pig cerebral cortex was 0.040 The KB value for antagonism of histamine-induced positive chronotropic responses in the right atrium of isolate guinea pigs was 0.041.Dalcotidine improves the quality of ulcer healing, and may contribute to a reduction in ulcer recurrence and relapse rates.

Quisultazine is a phenothiazine derivative with no central effects, can be classified as a non anti H2 antisecretory agent.

Bexlosteride (LY300502), a benzoquinolinone derivative, functions as a human type I 5α-reductase inhibitor. It demonstrates metabolic inhibition, antiproliferative, and antisecretory activities specifically in LNCaP human prostatic adenocarcinoma cell cultures, positioning it as a potent agent for prostate cancer research [1] [2].

Clidinium bromide (Ro 2-3773) , a synthetic anticholinergic agent, has been shown in experimental and clinical researchers to have a pronounced antisecretory and antispasmodic effect on the gastrointestinal tract. It can inhibit muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve cramps or stomach spasms or abdominal due to colicky abdominal diverticulitis, pain, and irritable bowel syndrome.

Troxipide (Aplace), a new-type systemic non-antisecretory gastric cytoprotective agent, which is mucus-secreting, anti-ulcer, and anti-inflammatory properties irrespective of pH of stomach or duodenum.

Pasireotide pamoate is a stable cyclohexapeptide somatostatin mimic. Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity.

Zaltidine is an antagonist of H2-receptor, and has the antisecretory action.

Ebrotidine (FI3542) is a competitive H2-receptor antagonist with Ki of 127.5 nM. Ebrotidine has a potent antisecretory activity and evidenced gastroprotection.

Picartamide demonstrates potent antisecretory and anti-ulcer properties, with an efficacy that exceeds cimetidine by at least tenfold.

Triampyzine is a compound with anticholinergic and antisecretory properties.

Deboxamet is a novel synthetic compound with anti-ulcer and antisecretory properties.

Triampyzine is a compound with anticholinergic and antisecretory properties.

BNTX (7-Benzylidenenaltrexone) is a selective δ1-opioid receptor antagonist. It competitively counteracts the antisecretory effects of DPDPE, Deltorphin 2, and DAMGO. BNTX is applicable in research focused on antinociceptive effects.

Pantoprazole-d8 (BY1023-d8) sodium is a deuterium-labeled version of Pantoprazole. Pantoprazole (BY1023) is an orally active, potent proton pump inhibitor (PPI). As a substituted benzimidazole, Pantoprazole effectively inhibits H+/K+-ATPase with an IC50 of 6.8 μM. It enhances pH stability and possesses antisecretory and anti-ulcer properties. When combined with Doxorubicin, Pantoprazole significantly extends tumor growth delay.

Oxyphencyclimine Hydrochloride (Ulcociclinina) is a synthetic tertiary amine and antimuscarinic agent with antispasmodic and antisecretory activities.

CS-526 is a proton pump inhibitor. The inhibitory mechanism of CS-526 on H+,K+-ATPase was a competitive antagonism to the K+ binding site of H+,K+-ATPase, and it was also a reversible inhibition. CS-526 has a potent antisecretory effect on gastric acid se